Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cationic steroid therapeutics - CSA Biotech/N8 Medical

Drug Profile

Research programme: cationic steroid therapeutics - CSA Biotech/N8 Medical

Alternative Names: Ceragenins; CGX-313; CSA 90; CSA-13; CSA-131; CSA-54; CSA-8; CSAs

Latest Information Update: 09 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brigham Young University
  • Developer Brigham Young University; Ceragenix Pharmaceuticals; N8 Medical
  • Class Small molecules; Steroids
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections; Fracture
  • Discontinued Methicillin-resistant Staphylococcus aureus infections; Vaccinia; Viral infections

Most Recent Events

  • 09 Apr 2018 Preclinical development in Bacterial-infections is still ongoing in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top